Cubist Systematic Strategies LLC Purchases 36,700 Shares of Mesoblast Limited $MESO

Key Points

• Cubist Systematic Strategies LLC increased its stake in Mesoblast Limited by 104.3% during the first quarter, owning 71,891 shares valued at approximately $897,000.
• Brokerages have mixed views on Mesoblast, with Canaccord Genuity upgrading the stock to a "strong-buy" rating, while Jefferies Financial Group downgraded it to a "hold," resulting in a consensus rating of "Buy" with a price target of $18.00.
• Mesoblast's stock performance shows a one-year range between $6.00 and $22.00, with the current price opening at $15.00 on Wednesday.

Cubist Systematic Strategies LLC lifted its holdings in shares of Mesoblast Limited (NASDAQ:MESO - Free Report) by 104.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 71,891 shares of the company's stock after purchasing an additional 36,700 shares during the period. Cubist Systematic Strategies LLC owned 0.06% of Mesoblast worth $897,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in MESO. Barclays PLC bought a new stake in shares of Mesoblast during the 4th quarter valued at about $38,000. BNP Paribas Financial Markets raised its stake in shares of Mesoblast by 86,566.7% in the fourth quarter. BNP Paribas Financial Markets now owns 2,600 shares of the company's stock worth $51,000 after purchasing an additional 2,597 shares during the last quarter. Bank of America Corp DE raised its stake in shares of Mesoblast by 1,503.3% in the fourth quarter. Bank of America Corp DE now owns 290,728 shares of the company's stock worth $5,756,000 after purchasing an additional 272,595 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Mesoblast by 1,174.2% during the first quarter. GAMMA Investing LLC now owns 85,513 shares of the company's stock valued at $1,067,000 after acquiring an additional 78,802 shares during the last quarter. Finally, Summit X LLC increased its position in shares of Mesoblast by 36.0% during the first quarter. Summit X LLC now owns 198,163 shares of the company's stock valued at $2,473,000 after acquiring an additional 52,508 shares during the last quarter. Institutional investors own 1.43% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on MESO. Jefferies Financial Group lowered Mesoblast from a "buy" rating to a "hold" rating in a report on Friday, July 18th. Canaccord Genuity Group raised Mesoblast to a "strong-buy" rating in a report on Tuesday, August 5th. Two analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $18.00.

Mesoblast Stock Up 4.3%

MESO stock traded up $0.64 during midday trading on Monday, hitting $15.46. The company's stock had a trading volume of 162,435 shares, compared to its average volume of 219,601. The firm's 50-day moving average is $14.57 and its 200-day moving average is $12.72. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.77 and a current ratio of 1.99. Mesoblast Limited has a 12 month low of $6.00 and a 12 month high of $22.00.

Mesoblast Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.